Scholar Rock Holding Stock
Scholar Rock Holding Corporation
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- David L. Hallal
- Employees
- 289
- Market cap
- $4.9 B
- IPO
- 25/05/2018
Scholar Rock Holding Corporation is a biopharmaceutical firm based in Cambridge, US, operating within the Healthcare sector and the Biotechnology industry. Founded in 2012, the company is dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Scholar Rock Holding stock: price history
1D
-1.8%
1W
-5.4%
1M
-19.2%
6M
-20.1%
YTD
-9.4%
1Y
+35.5%
2Y
+37.6%
5Y
+46.3%
10Y
–
Next earnings date
Next earnings date
13/11/2026 (in 27 days)
Volatility around earnings
~12% weaker price swings than usual
Ask the agents about Scholar Rock Holding
Analyst assessment of Scholar Rock Holding
PRICE TARGET LOW
US$58.00
CONSENSUS
US$70.45
MEDIAN
US$70.00
PRICE TARGET HIGH
US$84.00
1
STRONG BUY
12
BUY
1
HOLD
0
SELL
0
STRONG SELL
14
TOTAL · Buy
As of: 24/09/2026
Scholar Rock Holding stock metrics
P/E
-12.05
P/B
20.53
EV/EBITDA
-11.67
RETURN ON EQUITY
-43.3%
NET MARGIN
0.0%
DEBT/EQUITY
0.8
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
82.7%
FLOAT SHARES
100,685,749
AVG. DAILY VOLUME (30D)
2,180,584
Insider transactions (SEC)
Woods Keith
Hallal David
Peng Katie
Reed Joshua
Reed Joshua
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -1.8%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Scholar Rock Holding stock
What does Scholar Rock Holding do?
Scholar Rock Holding Corporation is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is David L. Hallal, the company employs around 289 people.
The IPO was on 25/05/2018; the stock trades on NASDAQ under the ticker SRRK.
What do analysts say about Scholar Rock Holding stock?
14 analysts rate the stock, the consensus is Buy (as of 24/09/2026).
The average price target is US$70.45, ranging from US$58.00 to US$84.00, with a median of US$70.00.
This is an external assessment, not a statement by Market Jury.
When does Scholar Rock Holding report next?
The next earnings date is 13/11/2026.
Around past earnings, price swings were roughly -12% stronger than usual.
Does Scholar Rock Holding pay a dividend?
No, Scholar Rock Holding currently does not pay a dividend.
Which stocks are comparable to Scholar Rock Holding?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Scholar Rock Holding stock analyzed?
Clicking "Analyze stock" lets five strategies assess Scholar Rock Holding against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.